Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte...

  • Main
  • 2017 / 04
  • Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte...
Cancer 2017 / 04

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer

Tarhini, Ahmad A., Rafique, Imran, Floros, Theofanis, Tran, Phu, Gooding, William E., Villaruz, Liza C., Burns, Timothy F., Friedland, David M., Petro, Daniel P., Farooqui, Mariya, Gomez-Garcia, Jose,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.30717
Date:
April, 2017
File:
PDF, 318 KB
english, 2017
Conversion to is in progress
Conversion to is failed